These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23307190)

  • 1. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.
    Ramani P; Headford A; May MT
    Virchows Arch; 2013 Feb; 462(2):203-9. PubMed ID: 23307190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
    Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
    Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathology of peripheral neuroblastic tumors].
    Wang L; He LJ; Shimada H
    Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinicopathologic features of peripheral neuroblastic tumors].
    Yang BF; Fu LB; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.
    Ramani P; Norton A; Somerville MS; May MT
    J Neurooncol; 2012 Jul; 108(3):375-83. PubMed ID: 22382784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.
    Ramani P; Somerville MS; May MT
    Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
    Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral neuroblastic tumours in eastern Denmark 1972-2002.
    Zimling ZG; Rechnitzer C; Rasmussen M; Petersen BL
    APMIS; 2007 Jan; 115(1):66-74. PubMed ID: 17223852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
    Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
    Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
    Suganuma R; Wang LL; Sano H; Naranjo A; London WB; Seeger RC; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Jarzembowski JA; Joshi VV; Navarro S; Peuchmaur M; Shimada H
    Pediatr Blood Cancer; 2013 Mar; 60(3):363-70. PubMed ID: 22744966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
    Ramani P; Nash R; Sowa-Avugrah E; Rogers C
    J Neurooncol; 2015 Oct; 125(1):103-11. PubMed ID: 26318737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peripheral neuroblastic tumors: anatomo pathological classification].
    Peuchmaur M
    Ann Pathol; 2004 Dec; 24(6):556-67. PubMed ID: 15785402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.
    Defferrari R; Mazzocco K; Ambros IM; Ambros PF; Bedwell C; Beiske K; Bénard J; Berbegall AP; Bown N; Combaret V; Couturier J; Erminio G; Gambini C; Garaventa A; Gross N; Haupt R; Kohler J; Jeison M; Lunec J; Marques B; Martinsson T; Noguera R; Parodi S; Schleiermacher G; Tweddle DA; Valent A; Van Roy N; Vicha A; Villamon E; Tonini GP
    Br J Cancer; 2015 Jan; 112(2):290-5. PubMed ID: 25356804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.
    Uccini S; Colarossi C; Scarpino S; Boldrini R; Natali PG; Nicotra MR; Perla FM; Mannarino O; Altavista P; Boglino C; Cappelli CA; Cozzi D; Donfrancesco A; Kokai G; Losty PD; McDowell HP; Dominici C
    Br J Cancer; 2006 Jul; 95(1):49-55. PubMed ID: 16755292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.